When are the cardiovascular and stroke risks too high? Pharmacotherapy for stroke prophylaxis-Reference-Cited by-同舟云学术

When are the cardiovascular and stroke risks too high? Pharmacotherapy for stroke prophylaxis

Published:2018-09-02 Issue:13 Volume:19 Page:1427-1440
ISSN:1465-6566
Container-title:Expert Opinion on Pharmacotherapy
language:en
Short-container-title:Expert Opinion on Pharmacotherapy

Author:

Gómez-Outes Antonio¹^ORCID,Suárez-Gea Mª Luisa¹,García-Pinilla Jose Manuel²³

Affiliation:

1. Division of Pharmacology and Clinical Drug Evaluation, Medicines for Human Use, Spanish Agency for Medicines and Medical Devices (AEMPS), Madrid, Spain

2. UGC de Cardiología y Cirugía Cardiovascular, Instituto de Biomedicina de Málaga (IBIMA), Hospital Universitario Virgen de la Victoria, Málaga, Spain

3. Centro de Investigación Biomédica en Red-Cardiovascular (CIBER-CV), Instituto de Salud Carlos III, Madrid, Spain

Funder

This manuscript was not funded

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14656566.2018.1511703

Reference81 articles.

1. Guidelines for the Primary Prevention of Stroke

2. Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack

3. Cardioembolic Stroke: Clinical Features, Specific Cardiac Disorders and Prognosis

4. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study

5. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Implementing green chemistry for synthesis of cholesterol-lowering statin drugs;Green Approaches in Medicinal Chemistry for Sustainable Drug Design;2020

2. N-Linoleyltyrosine Protects against Transient Cerebral Ischemia in Gerbil via CB2 Receptor Involvement in PI3K/Akt Signaling Pathway;Biological and Pharmaceutical Bulletin;2019-11-01